Form 483

Concord, Inc. dba Carlton's Dunwoody Pharmacy Form 483, 2016-01-13

FDA issued a Form 483 to Concord, Inc. dba Carlton's Dunwoody Pharmacy on 2016-01-13 with 10 public-safe observations.

483· Form 483 issuedHuman Drugs10 observations

Concord, Inc. dba Carlton's Dunwoody Pharmacy · Dunwoody, United States · Issued January 13, 2016

Overview

  • 10 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

13 Jan 2016
21 CFR 211.160(b)(4)

Calibration - at intervals, written program, remedial action

Cited by Rachael L Cook, Tamara J Henderson

13 Jan 2016
21 CFR 211.165(a)

Testing and release for distribution

Cited by Rachael L Cook, Tamara J Henderson

13 Jan 2016
21 CFR 211.166(a)

Lack of written stability program

Cited by Rachael L Cook, Tamara J Henderson

13 Jan 2016
21 CFR 211.188

Prepared for each batch, include complete information

Cited by Rachael L Cook, Tamara J Henderson

13 Jan 2016
21 CFR 211.22(c)

Approve or reject procedures or specs

Cited by Rachael L Cook, Tamara J Henderson

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(b)(4)Cited across public-safe Form 483 observations2x
21 CFR 211.165(a)Cited across public-safe Form 483 observations2x
21 CFR 211.166(a)Cited across public-safe Form 483 observations2x
21 CFR 211.188Cited across public-safe Form 483 observations2x
21 CFR 211.22(c)Cited across public-safe Form 483 observations2x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 10 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere